Gufic BioSciences Ltd (GUFICBIO) Declines -0.93% on Nov 15

November 15, 2017 - By Hazel Jackson

Shares of Gufic BioSciences Ltd (NSE:GUFICBIO) last traded at 85.65, representing a move of -0.93%, or -0.8 per share, on volume of 49,331 shares. After opening the trading day at 86.45, shares of Gufic BioSciences Ltd traded in a close range. Gufic BioSciences Ltd currently has a total float of 77.35 million shares and on average sees shares exchange hands each day. The stock now has a 52-week low of 40.1 and high of 99.6.

Indian Economy’s 2 Giants

The Indian stock market is one of the fastest growing equity markets in the world today. While it currently makes up only 12% to 14% of the country’s gross domestic product (GDP)’ far from the 70% corporate sector making up the entire GDP of the US, India’s corporate sector is rampantly thriving to become one of Asia’s leaders.

As of this month, nearly 8,000 companies are listed on the Indian equity market. More than half of these are listed on the two main stock exchanges in India combined’ the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE), representing about 4% of the country’s GDP.

Regular session on both the BSE and the MSE starts at 9:15 a.m. and concludes at 3:30 p.m.


The BSE, having been established in 1875, is the first stock exchange in Asia. It is also the first to acquire a permanent recognition under India’s Securities Contract Regulation Act of 1956.

Presently, the BSE is the 11th biggest stock exchange in the world with a total market capitalization of $1.70 trillion as of January 23, 2015. Moreover, it is also considered as one of the fastest stock exchanges in the world with a speed of six microseconds.

The BSE first touched its four-digit figure on July 25, 1990; the 5,000 mark on October 11, 1999; the 10,000 mark on February 6, 2006; the 20,000 mark on December 11, 2007; and the 30,000 mark on March 4, 2015, an event that was driven by the efforts of the Reserve Bank of India. Gufic BioSciences Ltd is a stock traded on the Indian stock exchange.

The biggest declines on the BSE happened during the onslaught of the 2008 Global Financial Crisis and when the Chinese central bank had suddenly moved to devalue the yuan. On January 21 and 22, 2008, the BSE has lost more than 2,000 points while on August 24, 2015, it has dropped over 1,700 points.

The SENSEX 30 is the free-float index that measures the 30 most active stocks on the BSE. It weighs stocks based on liquidity, market capitalization, floating-stock-adjustment depth, and other factors.


The NSE was founded in 1992 as the 1st demutualized electronic stock exchange in the country. Presently, it supports about 230,000 terminals throughout India. The NSE is owned and operated by the Indian Index Services and Products (IISP).

The NIFTY is the index that measures the 50 most active stocks across 24 industries on the NSE. Consequently, it covers a broader portion of India’s corporate sector than the SENSEX 30. Gufic BioSciences Ltd has relatively good liquidity.

The NIFTY has a base value of 1,000 and its base date is 1995. Like the SENSEX 30, it comprehensively weighs stocks based on liquidity, market capitalization, among others.

Investing in BSE and NSE stocks is strongly recommended for investors today. As the Indian economy continues to grow and become one of Asia’s biggest, it only makes sense to start betting on its equity market as early as now. Professional analysts might be interested how this will affect Gufic BioSciences Ltd.

More news for Gufic BioSciences Ltd (NSE:GUFICBIO) were recently published by:, which released: “Gufic Biosciences to merge Gufic Stridden Bio-Pharma with self” on November 25, 2016.‘s article titled: “Buy Gufic BioSciences, target Rs 78: Nirmal Bang Securities” and published on August 08, 2017 is yet another important article.

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products. The company has market cap of INR6.60 billion. The Company’s divisions include Pharma, including Formulations and Bulk Drugs, and Consumer. It has a 53.35 P/E ratio. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro Fe, Vipro M and Zad G, and Herbal, including Bocomo-Forte, River-Suspension, Sallaki-Liniment, Sallaki-Plus, Sallaki-XT and Smashit.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :